Supporting the release of stem cells from the bone marrow and increasing the number of circulating stem cells is probably the single most important thing you can do to improve your health.

Original post:

Science behind Enhancing Adult Stem Cells for wellbeing

McCain gaining on Romney, Researches can turn Skin Cells to Embryonic-like Stem Cells, Queen to broadcast Christmas message on YouTube.

More:

Come Back Kid

A fast paced tour of the University of Washington School of Medicine's new research lab complex. Situated in the bio-tech heart of Seattle's South Lake Union, the labs are conducting cutting edge research into cardiac stem cells, advanced MRI imaging, obesity and diabetes, and tumor vaccines.

Excerpt from:

Wow! UW Research labs

Elaine Fuchs, PhD, talks about the biology and clinical promise of skin stem cells, one of a series of lectures from The Yale School of Medicine Bicentennial Symposium, "Biomedicine in the New Century," which took place over April 28--29, 2011.

Read the original post:

Skin Stem Cells: Their Biology

see http://www.cellmedicine.com

Read more:

Cord Blood and Bone Marrow Stem Cells for Liver Failure

Elaine Fuchs, recently awarded a National Medal of Science, the United States' highest scientific award, discusses her lab's work on adult skin stem cells and mouse genetics.

Excerpt from:

Elaine Fuchs discusses research on skin and adult stem cells

http://www.cellmedicine.com the scientific basis for using cord blood stem cells to treat cerebral palsy

See the original post:

Stem Cell Therapy for Cerebral Palsy

Dr. Amit Patel gives a brief overview of stem cells and cardiac stem cell therapy.

See the rest here:

Cardiac Stem Cell Therapy

see http://www.cellmedicine.com

Excerpt from:

Expansion of Stem Cells by Valproic Acid

What would Your Life be Like if You Had Less Wrinkles? Look Younger Perhaps? Better Complexion Maybe

View original post here:
Stem Cell Therapy Cream: Less Wrinkles In 30 Days or Less Anti-Wrinkle Cream That Works

Stem Cell Injection treatment, also known as Bone Marrow Prolotherapy is demonstrated to the knee, hip, and ankle in this video, by Ross Hauser, MD. Dr

Excerpt from:
Stem Cell Injection Treatment - Stem Cell Therapy

(Part 2 of 3) Gary Steinberg, MD, Ph.D., spoke at the "Spotlight on Disease Team Awards: Sub-Cortical Stroke," an educational event presented at the CIRM Governing Board meeting on August 19, 2010.

Read this article:
Stem Cell Therapy for Stroke - Gary Steinberg, Stanford University

The meat industry has been misusing data to make it appear that E. coli contamination of meat is decreasing, said Barbara Kowalcyk of the Center for Foodborne Illness, Research and Prevention.

Executives from the American Meat Institute (AMI) have claimed success in the beef industry's efforts to reduce contamination with the dangerous E. coli strain O157:H7. According to the AMI, inspection data from the U.S. Department of Agriculture's (USDA's) Food Safety and Inspection Service show a 45 percent drop in E. coli prevalence between 2000 and 2008.

Yet Kowalcyk calls this is a misuse of data never intended for "year-to-year comparisons."

"USDA's E. coli ... testing program is strictly regulatory and was not statistically designed to estimate the prevalence of E. coli O157:H7 in raw ground beef," she said.

Although a 45 percent drop is in fact found in the data, Kowalcyk notes that different facilities were tested and different testing methods used each year. She called the AMI's conclusion as valid as comparing a person who weighed 300 pounds in 2000 to a different person weighing 150 pounds in 2008, then concluding that the average weight of the U.S. population had dropped 50 percent. Read more...

Ayurtox for Body Detoxification

One day 12-year-old Elizabeth McIngvale became obsessed with the number 42, which happened to be her mother’s age at the time, 11 years ago. When she washed her hands, she had to turn the sink on and off 42 times, get 42 pumps of soap and rinse her hands 42 times. Sometimes she decided that she actually needed to do 42 sets of 42. When she dressed, she put her right leg in and out of her pant leg 42 times, then the left. Even getting up from a chair took 42 attempts. She was afraid that if she did not follow her self-prescribed ritual, something terrible would happen to her family--they might die in a car accident, for instance. “Everything I did was completely exhausting and grueling,” she recalls. “I was probably doing 12 to 13 hours a day of rituals.”

McIngvale was diagnosed with obsessive- compulsive disorder (OCD), a psychiatric illness that afflicts 2 to 3 percent of Americans, not all of them as severely as McIngvale. Individuals with OCD experience debilitating recurrent and persistent thoughts, or obsessions, which they try to suppress or eliminate with rituals, known as compulsions. Compared with people who have other anxiety or mood disorders, adults with OCD are more likely to be single and unemployed. In fact, OCD is among the 10 most disabling medical and psychiatric conditions.

[More]

The underpinnings of autism are turning out to be even more varied than the disease's diverse manifestations. In four new studies and an analysis published June 8 researchers have added some major landmarks in the complex landscape of the disease, uncovering clues as to why the disease is so much more prevalent in male children and how such varied genetic mutations can lead to similar symptoms. [More]

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Donna Queen has joined ISCO's executive team. Ms. Queen will be primarily responsible for ISCO's wholly owned subsidiary Lifeline Skin Care's (Lifeline) brand identity and international marketing as well as broadening the range of Lifeline products currently available.


Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created the original Obagi Nu-Derm skincare system, which has since become the leading physician-dispensed brand of anti-aging skincare. Earlier Ms. Queen founded and led one of Virginia's largest advertising and marketing agencies, specializing in aesthetic and dermatological marketing and brand development.


Dr. Andrey Semechkin, President and CEO of ISCO, commented: "I'm very pleased that Ms. Queen has joined our team. Ms. Queen's industry experience and expertise particularly in marketing prescription-based products will be invaluable as we expand our skin care business and further enhance our line of products."


Ms. Queen adds, "I'm very excited to be joining such a dynamic, science-driven company. There have been no recent meaningful technological breakthroughs in skin care, but with ISCO's scientific leadership in stem cells and their knowledge of skin tissue physiology we have an opportunity to continue to deliver new and innovative treatments."


ISCO previously announced sales of approximately $1.1 million from the pilot direct-to-consumer launch of Lifeline's first two products, an anti-aging Day Serum and a Night Serum. These products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetics experts. The serums contain an extract from ISCO?s proprietary human parthenogenetic stem cells combined with antioxidants and botanically derived ingredients. Using these serums on a regular basis provides significant benefits to the skin including improvement in skin tone and elasticity and the improvement in the appearance of fine lines and wrinkles, results that have been independently established by clinical studies performed at industry-leading testing laboratories. The serums can be purchased by visiting Lifeline?s website at http://www.lifelineskincare.com and are also available at selected luxury spas and physicians' offices in the United States.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.



International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO, Lifeline Skin Care
ras@intlstemcell.com
or
Simon Craw, PhD
Vice President, ISCO
sc@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com